VariantInsight — protein variant triage for early biologics discovery
A decision-support app for biotech scientists that turns multimodal protein-model outputs into a plain-English wet-lab priority list: which variants to test first, which to skip, and which the model is unsure about.
Biotech R&D scientists planning experiments on protein variants for therapeutic or industrial use
- Rank-ordered candidate list with confidence flags grounded in structure and dynamics predictions
- One-click export to a CSV or LIMS-ready lab priority sheet
- Calibration warnings when a variant is outside the model's training distribution
- Side-by-side comparison of sequence-only versus structure-plus-dynamics predictions
Multimodal protein models are advancing fast in research, but biotech teams still lack a thin decision layer that turns model scores into actionable experimental queues; this gap is the product, not the model itself.
Cradle reports being trusted by top biopharma/industrial-bio R&D teams and claims scientists use it to prioritize experiments and shorten protein R&D timelines up to 12x — explicit validation of the exact need this idea targets.Cradle | Engineer better proteins, faster. ↗The AI engineering platform for biology ↗
Direct, well-funded competitors already occupy this niche: Cradle designs variants AND prioritizes experiments; AI.zymes (Rosetta/ProteinMPNN/ESMFold integration) and Generate:Biomedicines compete in protein design-to-test pipelines.AI.zymes - A modular platform for evolutionary enzyme design ↗Cradle Reviews, Alternatives, and Pricing updated July 2026 ↗
Biotech R&D software commands premium enterprise pricing with no public list prices; Cradle monetizes via pharma/industrial-bio partnerships and Benchling-style opaque enterprise contracts indicate strong willingness to pay.Cloud-based platform for biotech R&D | Benchling ↗Cradle | Engineer better proteins, faster. ↗
Protein engineering AI is a sustained, heavily funded trend (ESMFold, ProteinMPNN, AlphaFold, ProtMMLM) with multi-year roadmap in pharma; demand grows as models improve and wet-lab costs rise.
A thin decision/triage layer on top of open-weight models (ESMFold, ProteinMPNN, ProtMMLM) is buildable by a small team without training foundation models, though biotech sales cycles and validation requirements add friction.